FINAL PROGRAM   Print E-mail


Plenary sessions



Plenary sessions

Thursday October 1, 2009

08:00 Welcome address
  Pierre Youinou: Chairman of the Symposium
Pascal Olivard: President of the Brest University
Marc De Braekeleer: Dean of the Brest Medical School
François Cuillandre: Mayor of the City
   
08:30–11:00

DEBATE IN ETIOLOGY with the partnership of ARMOR-LUX

  Steve Krilis (Australia), Jacques-Olivier Pers (France) and Susumu Sugai (Japan)

08:30–08:50 Pathogenic virus or viruses?
  Harry Moutsopoulos (Greece)
   
08:50–09:10 Genetic basis of Sjögren's syndrome
 

 Juan-Manuel Anaya (Colombia)
   
09:10–09:30 Epigenetics
  Steffen Gay (Switzerland)
   
09:30–09:55 PANEL DISCUSSION
   
09:55–10:10 Sex hormones
  Yrjö Konttinen (Finland)
   
10:10–10:30 Are infections pathogenic or protective?
  Yehuda Shoenfeld (Israel)
   
10:30–11:00 PANEL DISCUSSION
   
11:00–11:30 Coffee Break
   
11:30–12:30 ETIOLOGY SESSION (continued)
  Peter Szodoray (Hungary), Takao Koike (Japan) and Gilbert Faure (France)
   
11:30–11:40 Immunization with α-fodrin on M3RP recapitulates the immunological findings in Sjögren's syndrome
 

 Jing He (China)
   
11:40–11:50 Candidate genes for Sjögren's syndrome susceptibility can be identified by genome wide scans with pooled DNA
  Beth Cobb (USA)
   
11:50–12:00 Hypomethylation and overexpression of CD70 in CD4+ T cells in primary Sjögren's syndrome
  Qianjin Lu (China)
   
12:00–12:10 Interaction between a genetic predisposition of IRF5 to autoimmunity and epigenetic dysregulation of this region
  Corinne Miceli-Richard (France)
   
12:10–12:20 A tale of two sexes and two cytokines in Sjögren's syndrome
  Cuong Nguyen (USA)
   
12:20–12:30 The immune regulatory rôle of vitamins A, D and E in Hungarian patients with primary Sjögren's syndrome
  Ildiko Horvath (Hungary)
   
12:30–14:00 Lunch
   
In parallel lunch-time Guided visit of 63 posters
 

With Udi Baharav (Israel), Jacques-Eric Gottenberg (France) and Pierre-Yves Hatron (France)
   
14:00–16:50 DEBATE IN CLINICS & BIOLOGY with the partnership of CRÉDIT AGRICOLE
  Yehuda Shoenfeld (Israel), Shige Sawada (Japan) and Manuel Ramos-Casals (Spain)
   
14:00–14:30 Pro/con debate: do IgG4-related disorders constitute a new clinical entity?
  Hiroki Takahashi (on behalf of the Japanese scientific community)
   
14:30–15:00 PANEL DISCUSSION
   
15:00–15:20 Deleterious effects of Sjögren's on the cornea
  Christophe Baudouin (France)
   
15:20–15:40 Does periodontitis pave the way to Sjögren's?
  Nicki Moutsopoulos (USA)
   
15:40–16:00 Other manifestations than oral and ocular in Sjogren's: what else?
  Cees Kallenberg (The Netherlands)
   
16:00–16:20 The revolution of proteomics
  Gianfranco Ferraccioli (Italy)
   
16:20–16:50 PANEL DISCUSSION
   
16:50–17:20 Coffee Break
   
17:20–18:40 CLINICS & BIOLOGY SESSION (continued)
  Guido Valesini (Italy), Sapan Pandya (India) and Roger Levy (Brazil)
   
17:20–17:30 Clinico-pathological analysis of 107 cases of IgG4-positive multi-organ lymphoproliferative syndrome
  Yasumufi Masaki (Japan)
   
17:30–17:40 Proteomic analysis of saliva: a tool to distinguish Sjögren's syndrome from other disorders
  Rosaria Talarico (Italy)
   
17:40–17:50 Defining the altered salivary gland tissue homeostasis prior to the onset of autoimmunity in Sjögren's syndrome
 

Nicolas Delaleu (Norway)

   
17:50–18:00 Evaluation of a large profile of autoantibodies in Sjögren's syndrome
  Shaye Kivity (Israel)
   
18:00–18:10 Connexion between immunological profile, systemic activity and apparition of another autoimmune disease in primary Sjögren's syndrome: results from a French cohort study of 419 patients
  Clothilde Martel (France)
   
18:10–18:20 Vascular events in primary Sjögren’s syndrome
  Roberta Priori (Italy)
   
18:20–18:30 Comparative clinical and immunomorphological characteristics of NHL in primary Sjögren's syndrome before and after introduction of parotid gland biopsy as a routine diagnostic method
  Samir Sedyshev (Russia)
   
18:30–18:40 Blood phagocytes of primary SS patients manifest aberrant phagocytosis of microbead in a manner similar to SLE: correlation with SS severity
  Menelaos Manoussakis (Greece)
   
19:00–20:30 On site dinner

 

Friday October 2, 2009

 

08:00–11:00 DEBATE IN PATHOPHYSIOLOGY with the partnership of CRÉDIT MUTUEL DE BRETAGNE
 

Harry Moutsopoulos (Greece), Thierry Defrance (France) and Thomas Dőrner (Germany)
   
08:00–08:20 Primary biliary cirrhosis: a model for Sjögren's?
  Eric Gershwin (USA)
   
08:20–08:40 The enigma of memory B lymphocytes
  Peter Lipsky (USA)
   
08:40–09:00 The cytotoxic T, Treg, Th17, Th1 and Th2 cell ballet
  Roland Jonsson (Norway)
   
09:00–09:30 PANEL DISCUSSION
   
09:30–09:50 BAFF, the conductor of the Sjögren’s orchestra
  Fabienne Mackay (Australia)
   
09:50–10:10 Aberrant chemokines and lymphoneogenesis
  Costantino Pitzalis (UK)
   
10:10–10:30 Toll-like receptors in Sjögren’s
  Thierry Defrance (France)
   
10:30–11:00 PANEL DISCUSSION
   
11:00–11:30 Coffee Break
   
11:30–12:40 PATHOPHYSIOLOGY SESSION (continued)
  Phil Cohen (USA), Fabienne Mackay (Australia) and Sophie Hillion (France)
   
11:30–11:40 Peripheral CD27+ IgD+ IgM+ B cells in patients with primary Sjögren's syndrome and healthy donors
  Arne Hansen (Germany)
   
11:40–11:50 Memory T cells require the continuous presence of B cells in a mouse model of Sjögren's syndrome
  Phil Cohen (USA)
   
11:50–12:00 Perturbations in B-cell homeostasis in primary Sjögren's syndrome
  Mustimbo Roberts (USA)
   
12:00–12:10 The relation between the expression of Id3 mRNA in B cells and sialoadenitis of Sjögren's syndrome
  Yasuko Nakagawa (Japan)
   
12:10–12:20 Evidence for a key role of lysosomal-associated protein transmembrane 5 in Sjögren's syndrome
  Shigasawa Sawada (Japan)
   
12:20–12:30 Correlation of focal lymphocytic sialadenitis with peripheral Th17, Treg, memory B lymphocytes in patients with primary Sjögren's syndrome
  Mengtao Li (China)
   
12:30–12:40 Psychological and personality features in primary Sjögren's syndrome: associations with autoantibodies to macropeptides
  Dimitrios Karaiskos (Greece)
   
12:40–14:00 Lunch
   
In parallel Guided visit of 67 posters
  With Arthur A.M. Bookman (Canada), Karsten Asmussen (Denmark) and Lucile Musset (France)
   
14:00–16:30 DEBATE IN TREATMENT with the partnership of BRITTANY FERRIES
  Peter Lipsky (USA), David Isenberg (UK) and Stefano Bombardieri (Italy)
   
14:00–14:20 Updating the audience with conventional therapies
  David Isenberg (UK)
   
14:20–14:40 Further insights into B cell-depletion
  Thomas Dőrner (Germany)
   
14:40–15:10 PANEL DISCUSSION
   
15:10–15:40 Biotherapies other than anti-CD20
  Robert Eisenberg (USA)
   
15:40–16:00 The point on the B-cell depleting trials currently in progress over the world in Sjögren's syndrome
  Alain Saraux (France)
   
16:00–16:30 PANEL DISCUSSION
   
16:30–17:00 Coffee Break
   
17:00–18:30 TREATMENT SESSION (continued)
  Steffen Gay (Switzerland), Valérie Devauchelle (France) and Troy Daniels (USA)
   
17:00–17:10 Effect of rituximab treatment on cytokine, chemokine profile in patients with primary Sjögren's syndrome
  Rodney Pollard (The Netherlands)
   
17:10–17:20 Efficacy and tolerability of rituximab in secondary Sjögren's syndrome therapy
  Alberto Migliore (Italy)
   
17:20–17:30 Rituximab: efficacy and safety in patients with primary Sjögren's syndrome
  Juan-Jose Scali (Argentina)
   
17:30–17:40 A double-blind, placebo-controlled crossover study using a latin square design to evaluate NGX267 in patients with xerostomia associated with Sjögren's syndrome
  Frederick Vivino (USA)
   
17:40–17:50 Long-term evaluation of idiotypic and anti-idiopathic response to the major epitope of La/SSB autoantigen in pregnant women at high risk for a child with congenital heart block (CHB) enrolled in the preventive IVIg therapy for CHB study
  John Routsias (Greece)
   
17:50–18:00 Effects of hydroxychloroquine salivary flow rates and oral complaints of Sjögren patients: a prospective sample study
  Yasmin Kabasakal (Turkey)
   
18:00–18:10 Combination therapy with corticosteroid, intravenous pulse cyclophosphamide and double-filtration plasmapheresis in neuromyelitis optica patients with Sjögren's syndrome
  Ichiro Mizushima (Japan)
   
18:10–18:20 Treating established experimental Sjögren's syndrome by blocking the lymphotoxin beta receptor pathway improves salivary gland function
  Anne Isine Bolstad (Norway)
   
18:20–18:30 Sustained effects of a supervised aerobic exercise program in women with primary Sjögren's syndrome: a 4-year follow-up
  Elke Theander (Sweden)
   

 

Saturday October 3, 2009

 

08:00–10:10

DEBATE IN EPIDEMIOLOGY with the partnership of Groupe EVEN
  Thanasis Tzioufas (Greece), Ayan Dinç (Turkey) and Ann Parke (USA)
   
08:00–08:20 Where are we now in epidemiology?
  Stefano Bombardieri (Italy)
   
08:20–08:40 Lymphoid malignancies: who, why, when, and where?
  Xavier Mariette (France)
   
08:40–09:00 The natural history of Sjögren’s syndrome
  Troy Daniels (USA)
   
09:00–09:20 The endless problem of assessing disease activity
  Claudio Vitali (Italy)
   
09:20–09:40 The quality of life in Sjögren’s syndrome
  Simon Bowman (UK)
   
09:40–10:10 PANEL DISCUSSION
   
10:10–10:40 Coffee Break
   
In parallel Guided visit of 61 posters
  With Juan-Jose Scali (Argentina), Carlos Vasconcelos (Portugal) and Jean-Marie Berthelot (France)
   
10:40–11:50 EPIDEMIOLOGY SESSION (continued)
  Loïc Guillevin (France), Frederick Vivino (USA) and Christophe Jamin (France)
   
10:40–10:50 Primary Sjögren's syndrome prevalence in a major metropolitan area in Brazil
  Valéria Valim (Brazil)
   
10:50–11:00 United Kingdom primary Sjögren's syndrome registry
  Wang-Fai Ng (UK)
   
11:00–11:10 Are there important differences in primary Sjögren's syndrome populations to be considered in evaluating outcomes?
  Frederick Vivino (USA)
   
11:10–11:20 The ocular sicca score: a simplified quantitative method for assessing keratoconjunctivitis sicca in patients enrolled in the Sjögren's international registry called the Sjögren's international clinical alliance
  Jack Whitcher (USA)
   
11:20–11:30 Sjögren syndrome or Sjögren disease? The histological and immunological bias caused by the 2002 criteria
  Manel Ramos-Casals (Spain)
   
11:30–11:40 Sjögren's syndrome requires a model approach for classification criteria development
  Stephen Shiboski (USA)
   
11:40–11:50 Health-related quality of life, employment and disability in patients with Sjögren's syndrome
  Petra Meiners (The Netherlands)

11:50–12:05 Conclusions of the "Ultrasonography scoring" Brest Task Force
  by Thanasis Tzioufas (Greece)
   
12:05–12:20 Conclusions of the "SS classification criteria" Group
  by Troy Daniels (USA)
   
12:20–12:35 Conclusions of the "Epigenetics and autoimmune disease" Study Group
  by Steffen Gay (Switzerland)
   
12:35–12:50 Conclusions of the EULAR Task Force for "Sjögren's syndrome monitoring"
  by Claudio Vitali (Italy)

12:50–13:10 Wrap-up, multinational projects and 11th Symposium kick-off
  Alain Saraux (co-chairman of this Symposium)
   
13:10–14:10 Lunch